<DOC>
	<DOCNO>NCT02215577</DOCNO>
	<brief_summary>Study Title Comparison two different model liver growth stimulation advance colorectal liver metastatic disease , ( LIGRO Trial ) enable liver resection Methodology Scandinavian Multiple Center Randomized Registry Based Clinical Trial Study duration The plan duration study participation individual subject inclusion follow-up 3 year Primary investigator : Per Sandstrom ( Link√∂ping ) Number subject 100 patient randomize 1:1 randomization Diagnosis main inclusion criterion Patients colorectal liver metastasis require liver resection , resectable one step future liver remnant/standardized total liver volume &lt; 30 % extrahepatic metastatic disease exclusion criterion address surgically future Overall goal To evaluate ALPPS approach superior PVE enabling patient , primarily unresectable due inadequate FLR , resect reach R0 situation acceptable level complication perioperative mortality . To evaluate ALPPS approach increase growth rate liver compare portal embolization portal ligation lead short treatment period . In addition investigator aim study ALPPS may reach goal without detectable improved difference tumor activity ( PFS OS ) , short recovery high proportion patient reach R0 . Hypothesis A high proportion patient resect ALPPS count rate resect compare previously establish method portal ligation embolization . This increased resection rate reduce R0 rate , increase rate Clavien grade 4 complication high ( H0 ) . The ALPPS approach increase growth rate compare portal embolization/ligation measure one week primary intervention .</brief_summary>
	<brief_title>ALPPS Versus PVE/PL</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>1 . By liver tumor board find accept inclusion 2 . Patients tumor burden colorectal liver metastasis 3 . Signed inform content 4 . Colorectal liver metastatic disease estimate FLR/sTLV &lt; 30 % 5 . Primary tumor extrahepatic disease possible resect patient liver first approach resection primary tumor . 1 . Cirrhosis 2 . Significant comorbidity render subject unsuitable major surgery 3 . Progressive disease preoperative oncological treatment 4 . Age &lt; 18 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>cancer , colorectal</keyword>
	<keyword>hepatectomy</keyword>
	<keyword>portal vein</keyword>
	<keyword>embolization</keyword>
	<keyword>two-stage</keyword>
</DOC>